Abstract
Introduction
The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody (mAb)-based technologies have rapidly developed into one of the major market segments of the pharmaceutical industry. By analyzing R&D pipelines and the platform technologies in use today, it is possible to better predict where the market will be in the next decade and to envisage which new innovative therapies will become market successes.
Research highlights
The second wave of therapeutic antibody technologies, encompassing optimized full size, fully human antibodies as well as the bits and pieces of individual antibody fragments and alternative binding domains/scaffolds is driving the formation of innovative technology platforms. While biotechs have led the race towards the discovery of novel technologies, big pharma has taken over the reigns for the development of many of these future therapeutic drugs.
In this report, BioSeeker Group has surveyed and categorized the technology platform status of over 100 companies and identified over 150 unique platforms that are shaping the current and future pipeline of monoclonal antibody therapeutics.
Scope of this report:
- A single source for market wide competing monoclonal antibody technologies in oncology
- Thorough examination of the leading cancer therapeutic antibody technologies
- The race towards the next generation of therapeutic antibodies
- Competing platforms for expression, delivery, and modification of antibodies
This report will:
- improve your competitor analysis
- allow you to assess the strengths/weaknesses of competing technologies
- outline R&D alignments
- allow you to assess the direction of future technologies
Pages: 163
Table of Contents
1 Executive Summary
2 About Cancer Highlights
3 Methodologies
4 Table of Contents
- 4.1 List of Boxes
- 4.2 List of Figures
- 4.3 List of Tables
5 Cancer Antibodies: The Growth Engine of the Pharmaceutical Market
- 5.1 Where We Stand Today
- 5.2 The Current Antibody Cancer Pipeline of Big Pharma and Biotech
- 5.3 Recent Changes in the Competitive Landscape of Monoclonal Antibody
Technologies
- 5.3.1 Big Pharma' s Race for Monoclonal Technologies
- 5.3.2 The Race to the First Approved Miniature Antibody
- 5.4 Technology Platform Approaches to Monoclonal Antibody Therapeutics
- 5.5 Drug Discovery and Development Platforms
6 Monoclonal Antibody Technologies- Protein Engineering and Library Platforms
- 6.1 From Mouse to Human Mabs
- 6.2 Human Antibodies from Transgenic Mice
- 6.3 Library Display Platforms
- 6.4 Antibodies Blown to Bits: From Full Length to Fragments
7 Classification of Technology Platforms by Monoclonal Antibody Specifics
- 7.1 Monoclonal Antibody Sources
- 7.1.1 B cells
- 7.1.2 Plasma
- 7.1.3 Cancer Stem Cells and Tumor Tissue
8 Active Immunotherapeutic Platforms Using Monoclonal Antibodies
- 8.1 Antigen Presenting Cells/Dendritic Cells
- 8.2 T cells
9 Monoclonal Immuoconjugates: Strategies and Platforms
- 9.1 Cytotoxin-Conjugated Antibody Platforms
- 9.2 Radioisotope-Conjugated Antibody Platforms
- 9.3 Antibody-Linker Platforms
- 9.4 Vasculature-Targeting Platforms
10 Monoclonal Antibody Expression Platforms
- 10.1 Mammalian Cell, Bacterial and Hybridoma Platform Technologies
- 10.2 Plant and Animal Platforms of Antibody Production
- 10.3 Monoclonal Antibody Processing Platforms
11 Monoclonal Antibody Platforms for Non-Protein Targets
- 11.1 Monoclonal Antibody Platforms for Carbohydrate
- 11.2 Monoclonal Antibody Platforms for Lipid
12 Post-Translational Modification Platforms
- 12.1 Glycosylation modification
13 Novel Strategies for Monoclonal Antibody Delivery
- 13.1 Gene Delivery and Transfer Technologies
- 13.2 Epidermal Delivery
14 Monoclonals Based on Non-IgG1 Immunoglobulin Structures
15 Alternative Non-Antibody Protein Binding Technologies
16 Monoclonal Antibody Technology Profiles _____(Truncated list)
- 16.1 AbGenomics
- 16.1.1 AbProt™
- 16.98.1 Human Engineering™ Technology HE™ technology
- 16.98.2 Microbial Expression Technology
18 Technology Platform Index
19 Company Index
4.1 List of Boxes
- Box 1: Desirable Immunogenicity from a Murine Antibody
- Box 2: mAb Competition for CD200
- Box 3: Using mAb Fragments to Bind Intracellular Targets
- Box 4: Cancer Stem Cells: A New Paradigm in Cancer Therapeutics
- Box 5: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies
4.2 List of Figures
- Figure 1: Developmental Status of the Antibody-based Pharmaceutical Pipeline in Oncology
- Figure 2: Top 10 Big Pharma Cancer mAb Pipeline
- Figure 3: Top 10 Biotech Company Cancer mAb Pipeline
- Figure 4: Investigator Country of Origin
- Figure 5: Company Breakdown by Platform Classification
4.3 List of Tables
- Table 1: Monoclonal Antibody Therapeutics Approved for Cancer Indications
- Table 2: Recent Noteworthy Acquisitions and Mergers in the mAb-based Oncology Therapeutic Market
- Table 3: TechPlatforms of Investigators Involved in Monoclonal Antibody Therapy of Cancer
- Table 4: Selected Companies and their Antibody Species Specificity
- Table 5: Pipeline of the Four Investigators with Transgenic Mouse Technology
- Table 6: Library Display Platform Technologies
- Table 7: Full Size Antibodies vs Antibody Fragments
- Table 8: Research Platforms for Cancer Immunotherapy using Antibody Fragments/Formats
- Table 9: Developmental Stage of Selected Bispecific Antibodies
- Table 10: Developmental Stage of Selected Trispecific Antibodies
- Table 11: Human Source Material for Monoclonal Antibody Platforms
- Table 12: Monoclonal Antibody Technology Platforms for Immune Cell Activation
- Table 13: Monoclonal Antibody Immunoconjugates Aprroved for Cancer Indications
- Table 14: Monoclonal Antibody Immunoconjugation Technologies
- Table 15: Radioisotope Platforms for mAb Technology
- Table 16: Technology Platforms Categorized by mAb-based Expression System
- Table 17: Non-Protein Targets of Monoclonal Antibody Platforms
- Table 18: Technology Platforms for Post-Translational Modification of Monoclonal Antibodies
- Table 19: Technology Platforms Specific for mAb Delivery
- Table 20: Company Platforms Based on Non-IgG1 Immunoglobulin Structures
- Table 21: Selected Companies with Cancer-Targeting Protein Therapeutics Based on Non-IgG Domains
